Clinical trial
A Study of All-Trans Retinoic Acid (ATRA) and Bryostatin in Patients With Acute…
NCT00136461 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00136461 |
|---|---|
| Title | A Study of All-Trans Retinoic Acid (ATRA) and Bryostatin in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) |
| Official title | A Randomized Phase II Trial of All-Trans Retinoic Acid and One of Two Schedules of Bryostatin 1 in Patients With Refractory Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Brigham and Women's Hospital |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Acute Myelogenous Leukemia, Myelodysplastic Syndrome |
| Intervention type | Drug |
| Interventions | All-trans retinoic acid, Bryostatin 1 |
| Enrollment | 40 |
| Start date | May 1, 1997 |
| Primary completion | Aug 1, 2000 |
| Completion | Aug 1, 2000 |
| First posted | Aug 29, 2005 |
| Last update posted | Mar 10, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: